var title_f9_2_9248="Cutting slit in foreskin";
var content_f9_2_9248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutting slit in foreskin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9248=[""].join("\n");
var outline_f9_2_9248=null;
var title_f9_2_9249="Stool diary sample";
var content_f9_2_9249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Stool diary (sample)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 602px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9249=[""].join("\n");
var outline_f9_2_9249=null;
var title_f9_2_9250="Thymic carcinoma Low";
var content_f9_2_9250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Poorly differentiated thymic carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows cystic changes within a thymic carcinoma. The cysts are filled with pale eosinophilic secretions and are reminiscent of an acquired multilocular thymic cyst. (Hematoxylin and eosin, magnification 2.5x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9250=[""].join("\n");
var outline_f9_2_9250=null;
var title_f9_2_9251="Fox Fordyce disease";
var content_f9_2_9251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Fox-Fordyce disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9251=[""].join("\n");
var outline_f9_2_9251=null;
var title_f9_2_9252="Longitudinal and transverse fractures of the phalanges";
var content_f9_2_9252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal and transverse fractures of the phalanges",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 584px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) This oblique examination&nbsp;of the right index finger reveals two separate fractures. There is a longitudinal fracture of the distal phalanx that traverses the joint. A second comminuted fracture in the proximal phalanx consists of a longitudinal component that traverses the proximal interphalangeal joint and a horizontal component through the mid to distal shaft.",
"    <br>",
"     (B) The fractures are highlighted.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9252=[""].join("\n");
var outline_f9_2_9252=null;
var title_f9_2_9253="Anatomy of the cervical esophagus - longitudinal";
var content_f9_2_9253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal section of the anatomy of the cervical esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows a longitudinal section of the anatomy of the cervical esophagus at the level of the sixth cervical vertebrae. Note the space between the oblique inferior constrictor muscle and the cricopharyngeum muscle, called Killian's triangle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9253=[""].join("\n");
var outline_f9_2_9253=null;
var title_f9_2_9254="Sitagliptin and metformin: Patient drug information";
var content_f9_2_9254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sitagliptin and metformin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/58/2983?source=see_link\">",
"     see \"Sitagliptin and metformin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4476968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Janumet&reg;;",
"     </li>",
"     <li>",
"      Janumet&reg; XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10107838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Janumet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A small number of people may have more acid in their blood. Metformin may cause this. It may happen in people whose liver or kidneys do not work the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702931",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sitagliptin, metformin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem, very bad kidney disease, or type 1 diabetes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having an x-ray with dye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop this drug for 2 days after you have an x-ray with dye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you are having surgery, if you have had a heart attack, bad infection, or stroke, or if you are 80 years of age or older and have not had your kidney function tested.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Too much acid in the blood (lactic acidosis) may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4156299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not split or break tablet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3311838",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Extended release tablets:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11912 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9254=[""].join("\n");
var outline_f9_2_9254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476968\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10107838\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028335\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028337\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028336\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028341\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028342\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028344\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028339\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028340\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028345\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028346\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/58/2983?source=related_link\">",
"      Sitagliptin and metformin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_2_9255="Repaglinide and metformin: Drug information";
var content_f9_2_9255=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Repaglinide and metformin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/29/5590?source=see_link\">",
"    see \"Repaglinide and metformin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6213597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6213591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      PrandiMet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6213594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Biguanide;",
"     </li>",
"     <li>",
"      Antidiabetic Agent, Meglitinide Derivative;",
"     </li>",
"     <li>",
"      Hypoglycemic Agent, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6213569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Daily doses should be divided and given 2-3 times daily with meals (maximum single dose: 4 mg/dose [repaglinide], 1000 mg/dose [metformin]; maximum daily dose: 10 mg/day [repaglinide], 2500 mg/day [metformin])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Patients currently taking repaglinide and metformin:",
"     </i>",
"     Initial doses should be based on (but not exceeding) the patient&rsquo;s current doses of repaglinide and metformin; titrate as needed to the maximum daily dose to achieve targeted glycemic control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Patients inadequately controlled on metformin alone:",
"     </i>",
"     Initial dose: repaglinide 1 mg/ metformin 500 mg twice daily with meals. Titrate slowly to reduce the risk of repaglinide-induced hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Patients inadequately controlled on a meglitinide alone:",
"     </i>",
"     Initial dose: metformin 500 mg twice daily plus repaglinide at a dose similar to (but not exceeding) the patient&rsquo;s current dose. Titrate slowly to reduce the risk of metformin-induced gastrointestinal adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6213836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6213570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use in renal impairment; metformin use is contraindicated in patients with renal impairment (serum creatinine &ge;1.5 mg/dL in males or &ge;1.4 mg/dL in females).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6213571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in patients with impaired liver function.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6213578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PrandiMet&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1/500: Repaglinide 1 mg and metformin hydrochloride 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     2/500: Repaglinide 2 mg and metformin hydrochloride 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6213593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6213574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer 15-30 minutes before meals to avoid risk of hypoglycemia/GI upset; if a meal skipped or patient is unable to take anything by mouth, do not administer dose.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6213600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM), as an adjunct to diet and exercise, in patients currently receiving or not adequately controlled on metformin and/or a meglitinide",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6213589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       PrandiMet&reg; may be confused with Avandamet&reg;, Prandin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6213582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The following information reflects the frequency of adverse effects experienced by patients who received the repaglinide/metformin fixed-dose combination product. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (19%), nausea (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (11%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6213606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to repaglinide, metformin, or any component of the formulation; renal impairment (serum creatinine &ge;1.5 mg/dL in males or &ge;1.4 mg/dL in females); acute or chronic metabolic acidosis (including diabetic ketoacidosis); concomitant administration of gemfibrozil",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6213607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: Some studies suggest that sulfonylureas may be associated with increased cardiovascular events. Theoretically, repaglinide may also increase cardiovascular events, but there are no long-term studies assessing this concern; metformin does not appear to share this risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: May cause hypoglycemia; appropriate patient selection, dosage, and patient education are important to avoid hypoglycemic episodes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis:",
"     <b>",
"      [U.S. Boxed Warning]: Lactic acidosis is a rare, but potentially severe consequence of therapy with metformin.",
"     </b>",
"     Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue metformin in clinical situations predisposing to hypoxemia, including conditions such as cardiovascular collapse, respiratory failure, acute myocardial infarction, acute congestive heart failure, and septicemia. The risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal/pituitary impairment: Use with caution in patients with adrenal and/or pituitary impairment; may be more susceptible to glucose-lowering effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus (type 1): Not indicated for use in patients with insulin-dependent diabetes mellitus (IDDM; type 1).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use caution in patients with heart failure requiring pharmacologic management, particularly in patients with unstable or acute heart failure; risk of lactic acidosis may be increased secondary to hypoperfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Avoid use in patients with impaired liver function due to potential for lactic acidosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: The combination product is not recommended for use in patients with renal impairment. Metformin is substantially excreted by the kidney; patients with renal function below the limit of normal for their age should not receive therapy. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gemfibrozil: Concomitant use has been reported to result in prolonged, severe hypoglycemia; the addition of itraconazole may augment the effect of gemfibrozil on repaglinide. Concurrent use of gemfibrozil is contraindicated with the repaglinide/metformin fixed-dose combination product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NPH insulin: Repaglinide is not indicated for use in combination with NPH insulin; in two studies, reports of myocardial ischemia (6 events) in patients using repaglinide plus insulin have caused concern. Further evaluation is required to assess the safety of this combination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more susceptible to glucose-lowering effects. Metformin should not be initiated in patients &ge;80 years of age unless normal renal function is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malnourished patients: Use with caution in malnourished patients; may be more susceptible to glucose-lowering effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iodinated contrast: Metformin therapy should  be temporarily discontinued prior to or at the time of  intravascular administration of iodinated contrast media (potential for acute alteration in renal function). Metformin should be withheld for 48 hours after the radiologic study and restarted only after renal function has been confirmed as normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical procedures: Therapy should be suspended for any surgical procedures (resume only after normal intake resumed and normal renal function is verified).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F6213660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6213661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Repaglinide. Management: Concurrent use of an azole antifungal with both repaglinide and gemfibrozil should be avoided.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: May increase the serum concentration of MetFORMIN. MetFORMIN may increase the serum concentration of Dalfampridine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May increase the serum concentration of Repaglinide. The addition of itraconazole may augment the effect of gemfibrozil on repaglinide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Repaglinide.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trospium: MetFORMIN may decrease the serum concentration of Trospium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6213664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid or limit ethanol (incidence of lactic acidosis may be increased; may cause hypoglycemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Food may delay and decrease the extent of absorption of metformin; the AUC of repaglinide may also be decreased. Metformin may decrease the absorption of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and/or folic acid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John&rsquo;s wort may increase the metabolism of repaglinide. The following herbs exhibit hypoglycemic activity; concomitant use may increase the risk of hypoglycemia: Alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6213601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6213602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination; therefore, repaglinide/metformin is classified as pregnancy category C. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6213604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metformin: Enters breast milk/not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6213605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6213573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken 15-30 minutes before meals to prevent hypoglycemia and decrease the risk of GI upset; if the patient misses a meal or is unable to take anything by mouth, the fixed-dose repaglinide/metformin combination agent should not be administered. Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy. Treatment may cause hypoglycemia; the patient should be able to recognize the signs and symptoms of hypoglycemia (palpitations, tachycardia, sweaty palms, diaphoresis, lightheadedness, etc). Monitor for signs and symptoms of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and/or folic acid deficiency; supplementation may be required.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (PrandiMet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-500 mg (100): $337.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-500 mg (100): $337.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6213576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Regular assessment of fasting blood glucose, postprandial blood glucose, and hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     ; initial and periodic monitoring of hematologic parameters (eg, hemoglobin/hematocrit, red blood cell indices) and renal function should be performed at least annually. Evaluation of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and folate should be performed if anemia is present.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6213669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6213667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination therapy; repaglinide and metformin act to improve glycemic control via two different mechanisms of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide is a nonsulfonylurea hypoglycemic agent which stimulates insulin release by blocking ATP-dependent potassium channels, depolarizing the membrane and facilitating calcium entry through calcium channels; increased intracellular calcium stimulates insulin release from the pancreatic beta cells.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metformin prevents hyperglycemia by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity via increased peripheral glucose uptake and utilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6213670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey CJ and Turner RC, &ldquo;Metformin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(9):574-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/8569826/pubmed\" id=\"8569826\" target=\"_blank\">",
"        8569826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeFronzo RA, &ldquo;Pharmacologic Therapy for Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1999, 131(4):281-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/10454950/pubmed\" id=\"10454950\" target=\"_blank\">",
"        10454950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunn CJ and Peters DH, &ldquo;Metformin: A Review of Its Pharmacologic Properties and Therapeutic Use in Diabetes Mellitus,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1995, 49(5):721-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/7601013/pubmed\" id=\"7601013\" target=\"_blank\">",
"        7601013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furlong NJ, Hulme SA, O'Brien SV, et al, &ldquo;Comparison of Repaglinide vs Gliclazide in Combination With Bedtime NPH Insulin in Patients With Type 2 Diabetes Inadequately Controlled With Oral Hypoglycaemic Agents,&rdquo;",
"      <i>",
"       Diabet Med",
"      </i>",
"      , 2003, 20(11):935-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/14632720/pubmed\" id=\"14632720\" target=\"_blank\">",
"        14632720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furlong NJ, Hulme SA, O'Brien SV, et al, &ldquo;Repaglinide Versus Metformin in Combination With Bedtime NPH Insulin in Patients With Type 2 Diabetes Established on Insulin/Metformin Combination Therapy,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2002, 25(10):1685-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/12351462/pubmed\" id=\"12351462\" target=\"_blank\">",
"        12351462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Josephkutty S and Potter JM, &ldquo;Comparison of Tolbutamide and Metformin in Elderly Diabetic Patients,&rdquo;",
"      <i>",
"       Diabet Med",
"      </i>",
"      , 1990, 7(16):510-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/2142054/pubmed\" id=\"2142054\" target=\"_blank\">",
"        2142054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lalau JD, Vermersch A, Hary L, et al, &ldquo;Type 2 Diabetes in the Elderly: An Assessment of Metformin,&rdquo;",
"      <i>",
"       Int J Clin Pharmacol Ther Toxicol",
"      </i>",
"      , 1990, 28(8):329-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/2272714/pubmed\" id=\"2272714\" target=\"_blank\">",
"        2272714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moses R, Slobodniuk R, Boyages S, et al, &ldquo;Effect of Repaglinide Addition to Metformin Monotherapy on Glycemic Control in Patients With Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 1999, 22(1):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/10333912/pubmed\" id=\"10333912\" target=\"_blank\">",
"        10333912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Niemi M, Backman JT, Neuvonen M, et al, &ldquo;Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics and Pharmacodynamics of Repaglinide: Potentially Hazardous Interaction Between Gemfibrozil and Repaglinide,&rdquo;",
"      <i>",
"       Diabetologia",
"      </i>",
"      , 2003, 46(3):347-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/12687332/pubmed\" id=\"12687332\" target=\"_blank\">",
"        12687332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9255/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quast U, Stephan D, Bieger S, et al, &ldquo;The Impact of ATP-Sensitive K+ Channel Subtype Selectivity of Insulin Secretagogues for the Coronary Vasculature and the Myocardium,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 2004, 53(Suppl 3):156-64.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9492 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9255=[""].join("\n");
var outline_f9_2_9255=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213597\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213591\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213594\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213569\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213836\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213570\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213571\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213578\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213593\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213574\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213600\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213589\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213582\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213606\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213607\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213660\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213661\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213664\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213601\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213602\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213604\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213605\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213573\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321833\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213576\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213669\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213667\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213670\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9492\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9492|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/29/5590?source=related_link\">",
"      Repaglinide and metformin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_2_9256="Nifedipine: Pediatric drug information";
var content_f9_2_9256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nifedipine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"    see \"Nifedipine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/27/31157?source=see_link\">",
"    see \"Nifedipine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adalat&reg; CC;",
"     </li>",
"     <li>",
"      Afeditab&reg; CR;",
"     </li>",
"     <li>",
"      Nifediac CC&reg;;",
"     </li>",
"     <li>",
"      Nifedical XL&reg;;",
"     </li>",
"     <li>",
"      Procardia XL&reg;;",
"     </li>",
"     <li>",
"      Procardia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F201400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adalat&reg; XL&reg;;",
"     </li>",
"     <li>",
"      Apo-Nifed PA&reg;;",
"     </li>",
"     <li>",
"      Mylan-Nifedipine Extended Release;",
"     </li>",
"     <li>",
"      Nu-Nifed;",
"     </li>",
"     <li>",
"      Nu-Nifedipine-PA;",
"     </li>",
"     <li>",
"      PMS-Nifedipine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianginal Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker, Dihydropyridine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"      see \"Nifedipine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Doses are usually titrated upward over 7-14 days; may increase over 3 days if clinically necessary:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertensive urgency:",
"     </b>",
"     Immediate release: Oral or \"bite and swallow\" (eg, bite capsule to release liquid contents then swallow): 0.1-0.25 mg/kg/dose; maximum single dose: 10 mg; may repeat if needed every 4-6 hours; monitor carefully; typically reserved for inpatient use; maximum daily dose: 1-2 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     (Blaszak, 2001; Egger, 2002; Singh, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     Current pediatric blood pressure guidelines do not recommend use (NHBPEP, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension (chronic treatment):",
"     </b>",
"     Extended release: Oral: Initial: 0.25-0.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     given once daily or divided in 2 doses per",
"     <b>",
"      day",
"     </b>",
"     ; do not exceed initial adult dose (30-60 mg/",
"     <b>",
"      day",
"     </b>",
"     ); titrate dose to effect; maximum dose: 3 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     up to 120 mg/",
"     <b>",
"      day",
"     </b>",
"     (NHBPEP, 2004; NHLBI, 2011); some centers use a higher maximum dose: 3 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     up to 180 mg/day (Flynn, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      High altitude pulmonary edema",
"     </b>",
"     (Pollard, 2001): Limited data available: Children and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Reserve treatment with NIFEdipine for unsatisfactory response to oxygen and/or altitude descent: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release: 0.5 mg/kg/dose every 8 hours; maximum dose: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release (preferred): 1.5 mg/kg/day given once daily or divided in 2 doses per",
"     <b>",
"      day",
"     </b>",
"     ; maximum dose: 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage adjustments should occur at 7- to 14-day intervals, to allow for adequate assessment of new dose; when switching from immediate release to sustained release formulations, use same total daily dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Chronic stable or vasospastic angina:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release: Initial: 10 mg 3 times daily; usual dose: 10-20 mg 3 times daily; coronary artery spasm may require up to 20-30 mg 3-4 times daily; single doses &gt;30 mg and total daily doses &gt;120 mg are rarely needed; maximum daily dose: 180 mg/",
"     <b>",
"      day",
"     </b>",
"     ;",
"     <b>",
"      Note:",
"     </b>",
"     Do not use for acute anginal episodes; may precipitate myocardial infarction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release: Initial: 30 or 60 mg once daily; maximum: 120-180 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Extended release: Initial: 30 or 60 mg once daily; maximum: 90-120 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      High altitude pulmonary edema",
"     </b>",
"     (Luks, 2010): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention: Extended release: 30 mg every 12 hours starting the day before ascent and may be discontinued after staying at the same elevation for 5 days or if descent initiated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: Extended release: 30 mg every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procardia&reg;: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 30 mg, 60 mg, 90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adalat&reg; CC: 30 mg, 60 mg, 90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Afeditab&reg; CR: 30 mg, 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nifediac CC&reg;: 30 mg [DSC], 60 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nifediac CC&reg;: 90 mg [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nifedical XL&reg;: 30 mg, 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procardia XL&reg;: 30 mg, 60 mg, 90 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Do not administer with grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Administer with or without food.  Liquid-filled capsule may be punctured and drug solution administered orally. When nifedipine is administered sublingually, only a small amount is absorbed sublingually; the observed effects are actually due to swallowing of the drug with subsequent rapid oral absorption. When measuring smaller doses from the liquid-filled capsules, consider the following concentrations (for Procardia&reg;) 10 mg capsule = 10 mg/0.34 mL; 20 mg capsule = 20 mg/0.45 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: Tablets should be swallowed whole; do not crush, break, chew, or divide. Adalat&reg; CC, Afeditab&reg; CR, Nifediac CC&reg;: Administer on an empty stomach (per manufacturer); other extended release products may not have this recommendation; consult product labeling.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adalat&reg; CC, Afeditab&reg; CR, Procardia XL&reg;: Store below 30&deg;C (86&deg;F); protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nifediac CC&reg;, Nifedical XL&reg;: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release capsules (Procardia&reg;): Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); prevent capsules from freezing; protect from light and moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Treatment of chronic stable or vasospastic angina (FDA approved in adults); has also been used for treatment of hypertensive emergency in pediatric patients and high altitude pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adalat&reg; CC, Afeditab&reg; CR, Nifediac CC&reg;: Treatment of hypertension alone or in combinations with other hypertensive agents (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Procardia XL&reg;, Nifedical XL&reg;: Treatment of chronic stable or vasospastic angina (FDA approved in adults); treatment of hypertension alone or in combination with other antihypertensive agents (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F201456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NIFEdipine may be confused with niCARdipine, niMODipine, nisoldipine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Procardia XL&reg; may be confused with Cartia XT&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depin [India] may be confused with Depen brand name for penicillamine [U.S.]; Depon brand name for acetaminophen [Greece]; Dipen brand name for diltiazem [Greece]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nipin [Italy and Singapore] may be confused with Nipent brand name for pentostatin [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F201454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: CHF, flushing, palpitation, peripheral edema (dose related), transient hypotension (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills difficulties in balance, dizziness, fatigue, fever, giddiness, headache, jitteriness, lightheadedness, mood changes, nervousness, shakiness, sleep disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Sexual difficulties",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, cramps, diarrhea, flatulence, gingival hyperplasia, heartburn, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: inflammation, joint stiffness, muscle cramps, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Chest congestion, cough, dyspnea, nasal congestion, sore throat, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, allergic hepatitis, alopecia, anemia, angina, angioedema, aplastic anemia, arrhythmia, arthritis with positive ANA, bezoars (Procardia XL&reg;), cerebral ischemia, depression, dysosmia, epistaxis, EPS, erectile dysfunction, erythema multiforme, erythromelalgia, exanthematous pustulosis, exfoliative dermatitis, facial edema, gastroesophageal reflux, gastrointestinal obstruction (Procardia XL&reg;), gastrointestinal ulceration (Procardia XL&reg;), gynecomastia, hematuria, ischemia, leukopenia, lip cancer (Friedman, 2012), memory dysfunction, migraine, myalgia, myoclonus, nocturia, paranoid syndrome, parotitis, periorbital edema, photosensitivity, polyuria, purpura, Stevens-Johnson syndrome, syncope, tachycardia, taste perversion, thrombocytopenia, tinnitus, toxic epidermal necrolysis, transient blindness, ventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reported with use of sublingual short-acting nifedipine: Acute MI, cerebrovascular ischemia, ECG changes, fetal distress, heart block, severe hypotension, sinus arrest, stroke, syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nifedipine or any component; concomitant use with strong CYP3A4 inducers (eg, rifampin); cardiogenic shock; additionally in adults: Immediate release preparation for treatment of urgent or emergent hypertension (Chobanian, 2003) and acute MI (Antman, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in cirrhotic patients as clearance of nifedipine is reduced, leading to increased systemic exposure; monitor closely for adverse effects or toxicity and consider dose adjustments. May increase frequency, duration, and severity of angina or precipitate acute MI during initiation of therapy. Use with caution in patients with CHF or aortic stenosis (especially with concomitant beta-blocker). Use with caution in patients taking CYP3A4 inhibitors; may result in increased nifedipine concentrations; monitor for adverse effects/toxicity and consider dose adjustments. Use with strong CYP3A4 inducers (eg, rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, and St John's wort) is contraindicated due to reduced bioavailability and efficacy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use extended release dosage forms with caution in patients with alterations in GI anatomy (eg, severe GI narrowing, history of GI cancer, obstruction, bowel resection, gastric bypass, vertical banded gastroplasty, colostomy), hypomotility disorders (constipation, GERD, ileus, obesity, hypothyroidism, diabetes), and concomitant medications (H",
"     <sub>",
"      2",
"     </sub>",
"     blockers, NSAIDs, laxatives, anticholinergic agents, levothyroxine); use of extended release forms have led to serious GI obstruction and (in rare cases) bezoars.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excessive hypotension may occur, especially during initiation of therapy or dosage increase (more common with concurrent beta-blocker therapy; monitor blood pressure closely); profound hypotension, MI, and death have been reported in adults when immediate release nifedipine has been used (orally or sublingually) for acute reduction of blood pressure (manufacturer does",
"     <b>",
"      not",
"     </b>",
"     recommend use of capsules for acute reduction of blood pressure); immediate release nifedipine is not FDA approved for long-term control of essential hypertension (appropriate studies to determine optimal dose or dosing interval have not been conducted). Mild to moderate peripheral edema may occur. Some dosage forms (eg, Adalat&reg; CC and Nifediac CC&reg;)  tablets contain lactose; do not use with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption syndromes",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F201443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (moderate), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May increase the serum concentration of NIFEdipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: May increase the serum concentration of NIFEdipine. Reported with sustained release nifedipine product.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of NIFEdipine. Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: NIFEdipine may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: May enhance the adverse/toxic effect of NIFEdipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of NIFEdipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: NIFEdipine may increase the serum concentration of VinCRIStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): NIFEdipine may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsule is rapidly absorbed orally if it is administered without food but may result in vasodilator side effects; administration with low-fat meals may decrease flushing. Grapefruit juice may significantly increase the oral bioavailability of nifedipine (avoid concurrent use). Food may decrease the rate but not the extent of absorption of Procardia XL&reg;. A high fat meal does not affect the extent of absorption of Adalat&reg; CC, but delays the time to peak and increases the peak concentration",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Nifedipine crosses the placenta. Use in pregnancy only when clearly needed and when the benefits outweigh the potential hazard to the fetus. Hypotension, IUGR reported. IUGR probably related to maternal hypertension. Nifedipine has been evaluated for the treatment of preterm labor. Tocolytics may be used for the short-term (48 hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth (ACOG, 2012). Nifedipine is ineffective for maintenance tocolytic therapy (ACOG, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, platelets, periodic liver enzymes; blood pressure, heart rate, signs and symptoms of CHF, peripheral edema",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium ions from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization; produces a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina; also reduces peripheral vascular resistance, producing a reduction in arterial blood pressure.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     \"Bite and swallow\": Within 1-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release: Within 20-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release: 2.5-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding: 92% to 98% (concentration-dependent);",
"     <b>",
"      Note:",
"     </b>",
"     Protein-binding may be significantly decreased in patients with renal or hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Capsule: 40% to 77%; Extended release: 84% to 89% relative to immediate release capsules; bioavailability increased with significant hepatic disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal: Immediate release: 2-5 hours; Extended release: 7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cirrhosis: 7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (60% to 80% as inactive metabolites); feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/27/31157?source=see_link\">",
"      see \"Nifedipine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol and grapefruit juice; rise slowly from prolonged sitting or lying position; insoluble shell of extended release tablet may appear in the stool (this is normal). May rarely cause photosensitivity reactions; avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); use a sunscreen; contact physician if reaction occurs",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10951001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 4 mg/mL oral suspension may be made with liquid capsules (",
"     <b>",
"      Note:",
"     </b>",
"     Concentration inside capsule may vary depending on manufacturer. Procardia&reg;: 10 mg capsule contains a concentration of 10 mg/0.34 mL [29.4 mg/mL]). Puncture the top of twelve 10 mg liquid capsules with one needle to create a vent. Insert a second needle attached to a syringe and extract the liquid; transfer to a calibrated bottle and add sufficient quantity of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; to make 30 mL. Label \"shake well\". Stable 90 days under refrigeration or at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Morosco RS, and Willhite EA, \"Stability of Nifedipine in Two Oral Suspensions Stored at Two Temperatures,\"",
"     <i>",
"      J Am Pharm Assoc",
"     </i>",
"     , 2002, 42(6):865-7.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin No. 127: &ldquo;Management of Preterm Labor,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2012, 119(6):1308.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/22617615/pubmed\" id=\"22617615\" target=\"_blank\">",
"        22617615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Adcock KG and Wilson JT, &ldquo;Nifedipine Labeling Illustrates the Pediatric Dilemma for Off-Patent Drugs,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2002, 109(2):319-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/11826214/pubmed\" id=\"11826214\" target=\"_blank\">",
"        11826214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, \"ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blaszak RT, Savage JA, and Ellis EN, \"The Use of Short-Acting Nifedipine in Pediatric Patients With Hypertension,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 139(1):34-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/11445791/pubmed\" id=\"11445791\" target=\"_blank\">",
"        11445791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/12748199 /pubmed\" id=\"12748199 \" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dilmen U, Cagf&uuml;lar MK, Senses A, et al, &ldquo;Nifedipine in Hypertensive Emergencies of Children,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1983, 137(12):1162-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/6637932 /pubmed\" id=\"6637932 \" target=\"_blank\">",
"        6637932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Egger DW, Deming DD, Hamada N, et al, \"Evaluation of the Safety of Short-Acting Nifedipine in Children With Hypertension,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2002, 17(1):35-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/11793132/pubmed\" id=\"11793132\" target=\"_blank\">",
"        11793132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT and Pasko DA, &ldquo;Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2000, 15(3-4):302-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/ 11149130 /pubmed\" id=\" 11149130 \" target=\"_blank\">",
"        11149130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedman GD, Asgari MM, Warton EM, et al, \"Antihypertensive Drugs and Lip Cancer in Non-Hispanic Whites,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2012, 6:1-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/22869299/pubmed\" id=\"22869299\" target=\"_blank\">",
"        22869299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lopez-Herce J, Albajara L, Cagigas P, et al, &ldquo;Treatment of Hypertensive Crisis in Children With Nifedipine,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 1988, 14(5):519-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/3221006/pubmed\" id=\"3221006\" target=\"_blank\">",
"        3221006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luks AM, McIntosh SE, Grissom CK, et al, \"Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness,\"",
"      <i>",
"       Wilderness Environ Med",
"      </i>",
"      , 2010, 21(2):146-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/20591379/pubmed\" id=\"20591379\" target=\"_blank\">",
"        20591379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, &ldquo;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , 2011, National Institutes of Health. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"      </a>",
"      . Accessed: June 11, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pollard AJ, Niermeyer S, Barry P, et al, \"Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001,\"",
"      <i>",
"       High Alt Med Biol",
"      </i>",
"      , 2001, 2(3):389-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/11682018/pubmed\" id=\"11682018\" target=\"_blank\">",
"        11682018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosen WJ and Johnson CE, &ldquo;Evaluation of Five Procedures for Measuring Nonstandard Doses of Nifedipine Liquid,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1989, 46(11):2313-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/2589350/pubmed\" id=\"2589350\" target=\"_blank\">",
"        2589350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh D, Akingbola O, Yosypiv I, et al, \"Emergency Management of Hypertension in Children,\"",
"      <i>",
"       Int J Nephrol",
"      </i>",
"      , 2012, 2012:420247.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/22577545/pubmed\" id=\"22577545\" target=\"_blank\">",
"        22577545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yiu V, Orrbine E, Rosychuk RJ, et al, \"The Safety and Use of Short-Acting Nifedipine in Hospitalized Hypertensive Children,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2004, 19(6):644-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/2/9256/abstract-text/15054645/pubmed\" id=\"15054645\" target=\"_blank\">",
"        15054645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12643 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-581423BC0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9256=[""].join("\n");
var outline_f9_2_9256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201399\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201400\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054394\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054387\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201374\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201360\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054398\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054390\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054397\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201456\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201454\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054402\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054386\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054385\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201443\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201369\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054404\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201370\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201385\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054393\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054384\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054400\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054401\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054392\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10951001\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12643\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12643|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=related_link\">",
"      Nifedipine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/27/31157?source=related_link\">",
"      Nifedipine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_2_9257="Dipylidium caninum life cycle";
var content_f9_2_9257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Dipylidium caninum life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gravid proglottids are passed intact in the feces or emerge from the perianal region of the host",
"    <strong>",
"     (1)",
"    </strong>",
"    . Subsequently, they release typical egg packets",
"    <strong>",
"     (2)",
"    </strong>",
"    . On rare occasions, proglottids rupture and egg packets are seen in stool samples. Following ingestion of an egg by the intermediate host (larval stages of the dog or cat flea",
"    <em>",
"     Ctenocephalides",
"    </em>",
"    spp), an oncosphere is released into the flea's intestine. The oncosphere penetrates the intestinal wall, invades the insect's hemocoel (body cavity), and develops into a cysticercoid larva",
"    <strong>",
"     (3)",
"    </strong>",
"    . The larva develops into an adult, and the adult flea harbors the infective cysticercoid",
"    <strong>",
"     (4)",
"    </strong>",
"    . The vertebrate host becomes infected by ingesting the adult flea containing the cysticercoid",
"    <strong>",
"     (5)",
"    </strong>",
"    . The dog is the principal definitive host for",
"    <em>",
"     Dipylidium caninum",
"    </em>",
"    . Other potential hosts include cats, foxes, and humans (mostly children)",
"    <strong>",
"     (6,7)",
"    </strong>",
"    . Humans acquire infection by ingesting the cysticercoid contaminated flea. This can be promulgated by close contact between children and their infected pets. In the small intestine of the vertebrate host the cysticercoid develops into the adult tapeworm which reaches maturity about one month after infection",
"    <strong>",
"     (8)",
"    </strong>",
"    . The adult tapeworms (measuring up to 60 cm in length and 3 mm in width) reside in the small intestine of the host, where they each attach by their scolex. They produce proglottids (or segments) which have two genital pores (hence the name \"double-pored\" tapeworm). The proglottids mature, become gravid, detach from the tapeworm, and migrate to the anus or are passed in the stool",
"    <strong>",
"     (1)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Dipylidium caninum infection. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Dipylidium.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Dipylidium.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9257=[""].join("\n");
var outline_f9_2_9257=null;
var title_f9_2_9258="Clinical manifestations and treatment of hypokalemia";
var content_f9_2_9258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and treatment of hypokalemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/2/9258/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/2/9258/contributors\">",
"     David B Mount, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/2/9258/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/2/9258/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/2/9258/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/2/9258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/2/9258/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/2/9258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3819676\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hypokalemia can be transiently induced by the entry of potassium into the cells, most cases result from unreplenished gastrointestinal or urinary losses due, for example, to vomiting, diarrhea, or diuretic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link\">",
"     \"Causes of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potassium replacement is primarily indicated when hypokalemia is due to potassium loss, and there is a significant deficit in body potassium. It is also warranted for acute therapy in disorders such as hypokalemic or thyrotoxic periodic paralysis in which the hypokalemia is due to redistribution of potassium into the cells in association with significant symptoms. Potassium is given cautiously in redistributive hypokalemia, since the hypokalemia is transient and the administration of too much potassium can lead to rebound hyperkalemia when the underlying process is corrected and potassium moves back out of the cells. The recommended regimens for acute therapy are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=see_link&amp;anchor=H12#H12\">",
"     \"Hypokalemic periodic paralysis\", section on 'Acute treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=see_link&amp;anchor=H7#H7\">",
"     \"Thyrotoxic periodic paralysis\", section on 'Acute treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal therapy in patients with hypokalemia due to potassium loss is dependent upon the severity of the potassium deficit. In addition, somewhat different considerations are required to minimize continued urinary losses due to diuretic therapy, or less often, to primary hyperaldosteronism.",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of hypokalemia will be reviewed here. The causes of and evaluation of patients with hypokalemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link\">",
"     \"Causes of hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9366?source=see_link\">",
"     \"Evaluation of the patient with hypokalemia\"",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3819731\">",
"    <span class=\"h1\">",
"     MANIFESTATIONS OF HYPOKALEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of the manifestations of hypokalemia tends to be proportionate to the degree and duration of the reduction in serum potassium. Symptoms generally do not become manifest until the serum potassium is below 3.0",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    unless the serum potassium falls rapidly or the patient has a potentiating factor, such as a predisposition to arrhythmia due to the use of digitalis. Symptoms usually resolve with correction of the hypokalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3819896\">",
"    <span class=\"h2\">",
"     Severe muscle weakness or rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness usually does not occur at serum potassium concentrations above 2.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    if the hypokalemia develops slowly [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/2\">",
"     2",
"    </a>",
"    ]. However, significant muscle weakness can occur at serum potassium concentrations below 2.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or at higher values with hypokalemia of acute onset, as occurs in hypokalemic or thyrotoxic periodic paralysis. In addition, the pathophysiology of weakness in these disorders is more complex. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14137?source=see_link&amp;anchor=H13#H13\">",
"     \"Myopathies of systemic disease\", section on 'Hypokalemic myopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pattern of weakness in hypokalemia is similar to that associated with hyperkalemia. Weakness usually begins in the lower extremities, progresses to the trunk and upper extremities, and can worsen to the point of paralysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of hyperkalemia in adults\", section on 'Severe muscle weakness or paralysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to causing muscle weakness, severe potassium depletion (serum potassium less than 2.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    can lead to muscle cramps, rhabdomyolysis, and myoglobinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Potassium release from muscle cells during exercise normally mediates vasodilation and an appropriate increase in muscle blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/8\">",
"     8",
"    </a>",
"    ]. Decreased potassium release due to profound hypokalemia can diminish blood flow to muscles during exertion, leading to ischemic rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/8\">",
"     8",
"    </a>",
"    ]. The clinical and pathologic abnormalities are reversible with potassium repletion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/4\">",
"     4",
"    </a>",
"    ]. A potential diagnostic problem is that the release of potassium from the cells with rhabdomyolysis can mask the severity of the underlying hypokalemia or even lead to normal or high values. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=see_link&amp;anchor=H31734850#H31734850\">",
"     \"Causes of rhabdomyolysis\", section on 'Electrolyte disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other manifestations of muscle dysfunction due to hypokalemia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory muscle weakness, which can be severe enough to result in respiratory failure and death.",
"     </li>",
"     <li>",
"      Involvement of gastrointestinal muscles, resulting in ileus and its associated symptoms of distension, anorexia, nausea, and vomiting. The hypokalemia in some of these patients is caused by concomitant diarrhea. As an example, several reports have noted an association between colonic pseudo-obstruction (Ogilvie&rsquo;s syndrome) and hypokalemia due to secretory diarrhea with an abnormally high fecal potassium content [",
"      <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=see_link&amp;anchor=H4#H4\">",
"       \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3819903\">",
"    <span class=\"h2\">",
"     Cardiac arrhythmias and ECG abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of arrhythmias may be seen in patients with hypokalemia. These include premature atrial and ventricular beats, sinus bradycardia, paroxysmal atrial or junctional tachycardia, atrioventricular block, and ventricular tachycardia or fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/2\">",
"     2",
"    </a>",
"    ]. Hypokalemia produces characteristic changes on the ECG although they are not seen in all patients. There is depression of the ST segment, decrease in the amplitude of the T wave, and an increase in the amplitude of U waves which occur at the end of the T wave (",
"    <a class=\"graphic graphic_waveform graphicRef73888 \" href=\"UTD.htm?18/38/19043\">",
"     waveform 1",
"    </a>",
"    ). U waves are often seen in the lateral precordial leads V4 to V6. Hypokalemia also prolongs the QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=see_link&amp;anchor=H12#H12\">",
"     \"ECG tutorial: Miscellaneous diagnoses\", section on 'Hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a large interpatient variability in the serum potassium concentration that is associated with progression of ECG changes or arrhythmias. In a carefully controlled trial of thiazide therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    there was a two-fold increase in ventricular arrhythmias (as detected by Holter monitoring) in the small proportion of patients in whom the serum potassium concentration fell to or below 3.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, the presence of concomitant factors, such as coronary ischemia, digitalis, increased beta adrenergic activity, and magnesium depletion, can promote arrhythmias; the last two of these cofactors can also lower the serum potassium concentration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epinephrine released during a stress response (as with coronary ischemia) drives potassium into the cells, possibly worsening preexisting hypokalemia. A similar effect can be seen with bronchodilator therapy with a beta adrenergic agonist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H17666854#H17666854\">",
"       \"Causes of hypokalemia\", section on 'Elevated beta-adrenergic activity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypokalemia may be associated with magnesium depletion (due, for example, to diuretics or diarrhea), both of which promote the development of arrhythmias. Hypokalemia and hypomagnesemia are associated with an increased risk of torsades de pointes, particularly in patients treated with drugs that prolong the QT interval or those with a genetic predisposition to the long QT syndrome. In addition to its direct proarrhythmic effect, hypomagnesemia can increase urinary potassium losses and lower the serum potassium concentration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H14#H14\">",
"       \"Acquired long QT syndrome\", section on 'Hypokalemia, hypomagnesemia, and hypocalcemia'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H8647773\">",
"       'Hypomagnesemia and redistributive hypokalemia'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3819925\">",
"    <span class=\"h2\">",
"     Renal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged hypokalemia can cause multiple structural and functional changes in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/15\">",
"     15",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired concentrating ability",
"     </li>",
"     <li>",
"      Increased ammonia production",
"     </li>",
"     <li>",
"      Increased bicarbonate reabsorption",
"     </li>",
"     <li>",
"      Altered sodium reabsorption",
"     </li>",
"     <li>",
"      Hypokalemic nephropathy",
"     </li>",
"     <li>",
"      Elevation in blood pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=see_link\">",
"     \"Hypokalemia-induced renal dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13060?source=see_link\">",
"     \"Potassium and hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45000008\">",
"    <span class=\"h2\">",
"     Glucose intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia reduces insulin secretion, which may play an important role in thiazide-associated diabetes. However, worsening glucose tolerance is much less common in the era of low-dose thiazide therapy (eg, 12.5 to 25 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_figure graphicRef69912 \" href=\"UTD.htm?37/49/38685\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H37#H37\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Thiazide diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3819951\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neuromuscular and cardiac symptoms induced by hypokalemia are related to alterations in the generation of the action potential [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/2\">",
"     2",
"    </a>",
"    ]. The ease of generating an action potential (called membrane excitability) is related both to the magnitude of the resting membrane potential and to the activation state of membrane sodium channels. Opening the sodium channels leads to the passive diffusion of extracellular sodium into the cells, which is the primary step in this process.",
"   </p>",
"   <p>",
"    According to the Nernst equation, the resting membrane potential is related to the ratio of the intracellular to the extracellular potassium concentration. In skeletal muscle, a reduction in the serum (extracellular) potassium concentration will increase this ratio and therefore hyperpolarize the cell membrane (that is, make the resting potential more electronegative); this impairs the ability of the muscle to depolarize and contract, leading to weakness. However, in some cardiac cells (such as Purkinje fibers in the conducting system), hypokalemia causes K2P1 channels, which are normally selective for potassium, to transport sodium into the cells, causing depolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This leads to increased membrane excitability and arrhythmias.",
"   </p>",
"   <p>",
"    Hypokalemia also delays ventricular repolarization by inhibiting the activity of potassium channels responsible for this component of the cardiac electrical cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60964434\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the presence of hypokalemia has been documented, attempts should be made from the history and laboratory findings to identify the cause of the hypokalemia, which is often apparent from the history (eg, vomiting, diarrhea, diuretic therapy). The patient should be evaluated for the functional manifestations of hypokalemia, and the potassium deficit should be estimated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9366?source=see_link\">",
"     \"Evaluation of the patient with hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2860406\">",
"     'Estimation of the potassium deficit'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The assessment of the hypokalemic patient begins with evaluation of muscle strength and obtaining an electrocardiogram to assess the cardiac consequences of the hypokalemia, with particular attention to the QT interval. At serum potassium concentrations below 2.5",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    severe muscle weakness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marked electrocardiographic changes may be present and require immediate treatment. (See",
"    <a class=\"local\" href=\"#H3819731\">",
"     'Manifestations of hypokalemia'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=see_link&amp;anchor=H12#H12\">",
"     \"ECG tutorial: Miscellaneous diagnoses\", section on 'Hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Telemetry or continuous ECG monitoring is indicated for hypokalemic patients with a prolonged QT, other ECG changes associated with hypokalemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    underlying cardiac issues that predispose to arrhythmia in the setting of hypokalemia (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity, myocardial infarction, underlying long QT syndrome, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3820122\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45915444\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of therapy in hypokalemia are to prevent or treat life-threatening complications (arrhythmias, paralysis, rhabdomyolysis, and diaphragmatic weakness), to replace the potassium deficit, and to diagnose and correct the underlying cause. The urgency of therapy depends upon the severity of hypokalemia, associated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    comorbid conditions, and the rate of decline in serum potassium concentration. The risk of arrhythmia from hypokalemia is highest in older patients, patients with organic heart disease, and patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potassium replacement is the mainstay of therapy in hypokalemia. Such therapy is clearly warranted in patients with hypokalemia due to renal or gastrointestinal losses. It should also be considered when hypokalemia is due to redistribution of potassium from the extracellular fluid into the cells (eg, hypokalemic periodic paralysis, insulin therapy) if serious complications such as paralysis, rhabdomyolysis, or arrhythmias are present or imminent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of hypokalemia\", section on 'Increased entry into cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8647773\">",
"    <span class=\"h3\">",
"     Hypomagnesemia and redistributive hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying cause of the hypokalemia should be identified as quickly as possible, particularly the presence of hypomagnesemia or redistributive hypokalemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hypokalemia may also have hypomagnesemia due to concurrent loss with diarrhea or diuretic therapy or, in patients with hypomagnesemia as the primary abnormality, renal potassium wasting [",
"      <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Such patients can be refractory to potassium replacement alone [",
"      <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/23\">",
"       23",
"      </a>",
"      ]. Thus, measurement of serum magnesium should be considered in patients with hypokalemia and, if present, hypomagnesemia should be treated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link&amp;anchor=H3#H3\">",
"       \"Signs and symptoms of magnesium depletion\", section on 'Hypokalemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=see_link\">",
"       \"Evaluation and treatment of hypomagnesemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A potential complication of potassium therapy in redistributive hypokalemia is rebound hyperkalemia as the initial process causing redistribution resolves or is corrected. Such patients can develop fatal hyperkalemic arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/3,24-27\">",
"       3,24-27",
"      </a>",
"      ]. The risk of rebound hyperkalemia is particularly high in patients with hypokalemic thyrotoxic periodic paralysis in whom rebound hyperkalemia has been described in 40 to 60 percent of treated attacks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=see_link&amp;anchor=H7#H7\">",
"       \"Thyrotoxic periodic paralysis\", section on 'Acute treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When increased sympathetic tone is thought to play a major role, the administration of a nonspecific beta blocker, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      , should be considered. The greatest experience is with acute attacks of hypokalemic thyrotoxic periodic paralysis. In such patients, high-dose oral propranolol or intravenous propranolol rapidly reverses the hypokalemia and paralysis seen in acute attacks, without rebound hyperkalemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=see_link&amp;anchor=H7#H7\">",
"       \"Thyrotoxic periodic paralysis\", section on 'Acute treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2860406\">",
"    <span class=\"h2\">",
"     Estimation of the potassium deficit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of the potassium deficit assumes that there is a normal distribution of potassium between the cells and the extracellular fluid. The most common settings in which this estimation",
"    <strong>",
"     does not apply",
"    </strong>",
"    is diabetic ketoacidosis or nonketotic hyperglycemia, and in redistributive causes of hypokalemia such as hypokalemic periodic paralysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of hypokalemia\", section on 'Increased entry into cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goals of potassium replacement in patients with hypokalemia due to potassium losses are to rapidly raise the serum potassium concentration to a safe level and then replace the remaining deficit at a slower rate over days to weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/3,20,28\">",
"     3,20,28",
"    </a>",
"    ]. Estimation of the potassium deficit and careful monitoring of the serum potassium helps to prevent hyperkalemia due to excessive supplementation. This is not an uncommon outcome in hospitalized patients since, in one report, one in six patients developed mild hyperkalemia following potassium administration for hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/29\">",
"     29",
"    </a>",
"    ] The risk of overcorrection is increased in patients with a reduced glomerular filtration rate.",
"   </p>",
"   <p>",
"    The potassium deficit varies directly with the severity of hypokalemia. In different studies, the serum potassium concentration fell by approximately 0.27",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 100 meq reduction in total body potassium stores [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/3,28,30\">",
"     3,28,30",
"    </a>",
"    ] and, in chronic hypokalemia, a potassium deficit of 200 to 400 meq is required to lower the serum potassium concentration by 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/30\">",
"     30",
"    </a>",
"    ]. However, these estimates are only an approximation of the amount of potassium replacement required to normalize the serum potassium concentration and careful monitoring is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12019917\">",
"    <span class=\"h3\">",
"     Uncontrolled diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In diabetic ketoacidosis or a hyperosmolar hyperglycemic state (nonketotic hyperglycemia), hyperosmolality and insulin deficiency favor the movement of potassium out of cells. As a result, the serum potassium concentration at presentation may be normal or even elevated despite a marked potassium deficit due to urinary and, in some patients, gastrointestinal losses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/31\">",
"     31",
"    </a>",
"    ]. The initiation of insulin therapy and fluid replacement will lower the serum potassium toward the level appropriate for the potassium deficit. Potassium supplementation is usually begun once the serum potassium concentration is 4.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or lower.",
"   </p>",
"   <p>",
"    Occasional patients with uncontrolled diabetes have more marked potassium loss and are hypokalemic at presentation. Such patients require aggressive potassium replacement (20 to 30",
"    <span class=\"nowrap\">",
"     meq/hour),",
"    </span>",
"    which can be achieved by the addition of 40 to 60 meq of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    to each liter of one-half isotonic saline. Since insulin will worsen the hypokalemia, insulin therapy should be",
"    <strong>",
"     delayed",
"    </strong>",
"    until the serum potassium is above 3.3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    to avoid possible complications of hypokalemia such as cardiac arrhythmias and respiratory muscle weakness. (See",
"    <a class=\"local\" href=\"#H18820461\">",
"     'Intravenous potassium repletion'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3819731\">",
"     'Manifestations of hypokalemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Potassium depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3820784\">",
"    <span class=\"h2\">",
"     Potassium preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium can be administered as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=see_link\">",
"     potassium phosphate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"     potassium bicarbonate",
"    </a>",
"    or its precursors (potassium citrate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36036?source=see_link\">",
"     potassium acetate",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20515?source=see_link\">",
"     potassium gluconate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/3,20,28\">",
"     3,20,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice among these preparations varies with the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"       Potassium bicarbonate",
"      </a>",
"      or its precursors are preferred in patients with hypokalemia and metabolic acidosis (eg, renal tubular acidosis or diarrhea) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/20,28\">",
"       20,28",
"      </a>",
"      ]. Only",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36036?source=see_link\">",
"       potassium acetate",
"      </a>",
"      is available for intravenous use.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=see_link\">",
"       Potassium phosphate",
"      </a>",
"      should be considered only in the rarely seen patients with hypokalemia and hypophosphatemia, as might occur with proximal (type 2) renal tubular acidosis associated with Fanconi syndrome and phosphate wasting [",
"      <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/28,32,33\">",
"       28,32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       Potassium chloride",
"      </a>",
"      is preferred in all other patients for two major reasons [",
"      <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/1\">",
"       1",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with hypokalemia and metabolic alkalosis are often chloride depleted due, for example, to diuretic therapy or vomiting. In such patients, chloride depletion contributes to maintenance of the metabolic alkalosis by enhancing renal bicarbonate reabsorption and may contribute to potassium wasting as sodium is reabsorbed in exchange for secreted potassium rather than with chloride [",
"      <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/3,34,35\">",
"       3,34,35",
"      </a>",
"      ]. It has been estimated that administration of non-chloride-containing potassium salts in the presence of metabolic alkalosis results in the retention of only 40 percent as much potassium as the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link&amp;anchor=H4#H4\">",
"       \"Pathogenesis of metabolic alkalosis\", section on 'Chloride depletion'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=see_link&amp;anchor=H9857754#H9857754\">",
"       \"Treatment of metabolic alkalosis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       Potassium chloride",
"      </a>",
"      raises the serum potassium concentration at a faster rate than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"       potassium bicarbonate",
"      </a>",
"      . Chloride is primarily an extracellular anion that does not enter cells to the same extent as bicarbonate, thereby promoting maintenance of the administered potassium in the extracellular fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/36\">",
"       36",
"      </a>",
"      ] In addition, potassium bicarbonate may partially offset the benefits of potassium administration by aggravating metabolic alkalosis, if present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    can be given in crystalline form (salt substitutes), as a liquid, or in a slow-release tablet or capsule. Salt substitutes contain 50 to 65 meq per level teaspoon; they are safe, well tolerated, and much less expensive than the other preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/37\">",
"     37",
"    </a>",
"    ]. Liquid forms of potassium chloride are also inexpensive, but are often unpalatable. Nevertheless, they may be preferred in patients with an enteral feeding tube or who are unable to swallow tablets. Slow-release tablets are better tolerated, but they have been associated with gastrointestinal ulceration and bleeding, which have been ascribed to local accumulation of high concentrations of potassium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/38\">",
"     38",
"    </a>",
"    ]. The risk is relatively low, and even lower with microencapsulated preparations (eg, microK or Klor-Con) compared to wax matrix tablets [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing the intake of potassium-rich foods, such as oranges and bananas (",
"    <a class=\"graphic graphic_table graphicRef53492 \" href=\"UTD.htm?39/21/40284\">",
"     table 1",
"    </a>",
"    ), is",
"    <strong>",
"     less effective",
"    </strong>",
"    , in part because dietary potassium is predominantly in the form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=see_link\">",
"     potassium phosphate",
"    </a>",
"    or potassium citrate which, as mentioned earlier in this section, results in the retention of only 40 percent as much potassium as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, the potassium concentration is relatively low in fruit (eg, approximately 2.2",
"    <span class=\"nowrap\">",
"     meq/inch",
"    </span>",
"    [0.9",
"    <span class=\"nowrap\">",
"     meq/cm]",
"    </span>",
"    in bananas) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/39\">",
"     39",
"    </a>",
"    ]. As a result, it would take two to three bananas to provide 40 meq.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3820183\">",
"    <span class=\"h3\">",
"     Intravenous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     Potassium chloride",
"    </a>",
"    can be given intravenously to patients who are unable to take oral therapy or as an adjunct to oral replacement in patients who have severe symptomatic hypokalemia. (See",
"    <a class=\"local\" href=\"#H18820461\">",
"     'Intravenous potassium repletion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23441650\">",
"    <span class=\"h2\">",
"     Ongoing losses and the steady state",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations for potassium replacement in the following sections assume that there are no ongoing losses (eg, vomiting, diarrhea, nasogastric suction, diuretic therapy) and that the patient does not have a chronic potassium wasting condition such as diuretic therapy, primary aldosteronism, or Gitelman or Bartter syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with ongoing losses, the rate of potassium administration recommended below must be increased by the rate of potassium loss to produce the desired rate of potassium repletion.",
"     </li>",
"     <li>",
"      Stable patients with chronic diuretic therapy (at a fixed dose), primary aldosteronism (unless aldosterone secretion increases), or Gitelman or Bartter syndrome typically do",
"      <strong>",
"       not",
"      </strong>",
"      develop progressive hypokalemia because the increased urinary potassium losses are balanced by hypokalemia-induced potassium retention. The net effect is a new steady state in which potassium intake and output are in balance, with a lower than normal serum potassium concentration. In such patients, usual rates of potassium repletion produce only modest elevations in serum potassium. As soon as the serum potassium rises, there is less hypokalemia-induced potassium retention and most of the administered potassium is excreted in the urine. A potassium-sparing diuretic is usually preferred in such patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H838162389#H838162389\">",
"       \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'The steady state'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features of primary aldosteronism\", section on 'The steady state'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H465021\">",
"    <span class=\"h2\">",
"     Potassium-sparing diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two classes of potassium-sparing diuretics: blockers of the cortical collecting tubule sodium channels (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    ); and the aldosterone (mineralocorticoid receptor) antagonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ). With respect to treating hypokalemia, these drugs are used in patients with renal potassium wasting in whom, as noted in the preceding section, potassium supplements may not be sufficiently effective.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     Amiloride",
"    </a>",
"    is usually preferred to a mineralocorticoid receptor antagonist because it is better tolerated. Primary aldosteronism is an important exception, since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    is preferred to block apparent adverse effects of excess aldosterone on the heart and vascular system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features of primary aldosteronism\", section on 'Cardiovascular risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of primary aldosteronism\", section on 'Aldosterone antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potassium-sparing diuretic in combination with potassium supplements should be used only with careful monitoring of the serum potassium since the risk of hyperkalemia is increased. This may be a particular problem in patients with moderately severe to severe heart failure in whom several factors may act together to markedly reduce urinary potassium excretion (decreased renal perfusion due to the fall in cardiac output, therapy with an angiotensin inhibitor, and therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ). Among patients with heart failure, aldosterone antagonists should be given only if the serum creatinine is less than or equal to 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in men and 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in women and the serum potassium is less than 5.0",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Risk of hyperkalemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link&amp;anchor=H14#H14\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Major society guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3820392\">",
"    <span class=\"h2\">",
"     Mild to moderate hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most hypokalemic patients have a serum potassium concentration of 3.0 to 3.4",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    This degree of potassium depletion usually produces no symptoms. Exceptions include patients with heart disease (particularly if they are taking digitalis or certain other antiarrhythmic drugs or are undergoing cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]) and patients with cirrhosis, in whom hypokalemia can increase ammonia generation and promote the development of hepatic encephalopathy.",
"   </p>",
"   <p>",
"    Treatment of mild to moderate hypokalemia depends upon the cause of the hypokalemia and acid-base status:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with gastrointestinal losses are treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      if they have metabolic alkalosis (as usually seen with vomiting) or a normal serum bicarbonate concentration, and with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"       potassium bicarbonate",
"      </a>",
"      (or potassium citrate or acetate) in the presence of metabolic acidosis (as seen with diarrhea or renal tubular acidosis). Treatment is usually started with 10 to 20 meq of potassium given two to four times per day (20 to 80",
"      <span class=\"nowrap\">",
"       meq/day),",
"      </span>",
"      depending upon the severity of the hypokalemia. (See",
"      <a class=\"local\" href=\"#H3820784\">",
"       'Potassium preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast, potassium supplements at usual doses produce only modest elevations in serum potassium in patients with hypokalemia due to renal potassium wasting (eg, chronic diuretic therapy, primary aldosteronism). As soon as the serum potassium rises, there is less hypokalemia-induced potassium retention and most of the administered potassium is excreted in the urine. Thus, a potassium-sparing diuretic is likely to be more effective.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"       Amiloride",
"      </a>",
"      is usually preferred to an aldosterone antagonist because it is better tolerated. Primary aldosteronism is an important exception, since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      is preferred to block apparent adverse effects of excess aldosterone on the heart and vascular system. (See",
"      <a class=\"local\" href=\"#H23441650\">",
"       'Ongoing losses and the steady state'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H465021\">",
"       'Potassium-sparing diuretics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with mild to moderate hypokalemia who are treated with potassium supplements are typically treated with oral therapy. Patients who cannot take oral therapy require intravenous repletion. Sequential monitoring of the serum potassium is essential to determine the response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3820210\">",
"    <span class=\"h2\">",
"     Severe or symptomatic hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium must be given more rapidly to patients with hypokalemia that is severe (serum potassium less than 2.5 to 3.0",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    or symptomatic (arrhythmias, marked muscle weakness, or rhabdomyolysis).",
"   </p>",
"   <p>",
"    A potential diagnostic and therapeutic problem in patients with hypokalemia-induced rhabdomyolysis is that the release of potassium from the muscle cells can mask the severity of the underlying hypokalemia or even lead to normal or elevated values at presentation or after potassium supplementation. If the serum potassium is normal or elevated at baseline, it will not be possible to be certain that underlying hypokalemia was responsible for the rhabdomyolysis and initial potassium therapy in such patients is not warranted and may be dangerous. In patients who present with hypokalemia, potassium therapy can be initiated with repeated monitoring of the serum potassium (eg, every four to six hours initially).",
"   </p>",
"   <p>",
"    Particular caution must be exercised when repleting potassium in patients with a concurrent disorder that, when treated, will tend to drive potassium into the cells and worsen the hypokalemia. The two main examples are insulin therapy in diabetic ketoacidosis or nonketotic hyperglycemia, and bicarbonate therapy in metabolic acidosis with a normal anion gap.",
"   </p>",
"   <p>",
"    Potassium repletion is most easily accomplished orally but can be given intravenously. The serum potassium concentration can transiently rise by as much as 1 to 1.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    after an oral dose of 40 to 60 meq, and by as much as 2.5 to 3.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    after 135 to 160 meq [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The serum potassium concentration will then fall back toward baseline over a few hours, as most of the exogenous potassium is taken up by the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/44\">",
"     44",
"    </a>",
"    ]. A patient with a serum potassium concentration of 2.0",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    for example, may have a 400 to 800 meq potassium deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/30\">",
"     30",
"    </a>",
"    ]. In patients with severe hypokalemia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    can be given orally in doses of 40 meq, three to four times per day or, particularly in patients also treated with intravenous potassium, 20 meq every two to three hours.",
"   </p>",
"   <p>",
"    As noted in the preceding section, potassium supplements at usual doses produce only modest elevations in serum potassium in patients with hypokalemia due to renal potassium wasting (eg, chronic diuretic therapy, primary aldosteronism). Thus, a potassium-sparing diuretic is likely to be more effective. &nbsp;",
"   </p>",
"   <p>",
"    Careful monitoring is essential in patients treated with potassium. We suggest that the serum potassium should initially be measured every two to four hours to ascertain the response to therapy. If tolerated, this regimen should be continued until the serum potassium concentration is persistently above 3.0 to 3.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and symptoms or signs attributable to hypokalemia have resolved. Thereafter, the dose and frequency of administration can be reduced to that used in mild to moderate hypokalemia since aggressive repletion is no longer required and gastric irritation can be avoided. (See",
"    <a class=\"local\" href=\"#H3820392\">",
"     'Mild to moderate hypokalemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18820461\">",
"    <span class=\"h3\">",
"     Intravenous potassium repletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     Potassium chloride",
"    </a>",
"    can be given intravenously as an adjunct to oral replacement in patients who have severe symptomatic hypokalemia and in patients with less severe hypokalemia who are unable to take oral medications. Potential constraints to intravenous therapy for severe hypokalemia include a risk of volume overload in susceptible subjects and hyperkalemia due to excessive repletion.",
"   </p>",
"   <p>",
"    A saline rather than a dextrose solution should be used for initial therapy, since the administration of dextrose stimulates the release of insulin which drives extracellular potassium into the cells. This can lead to a transient 0.2 to 1.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    reduction in the serum potassium concentration, particularly if the solution contains only 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of potassium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/3,45\">",
"     3,45",
"    </a>",
"    ]. The transient reduction in serum potassium can induce arrhythmias in susceptible patients, such as those taking digitalis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The necessity for aggressive intravenous potassium replacement most commonly occurs in patients with diabetic ketoacidosis or hyperosmolar hyperglycemic state (nonketotic hyperglycemia). These patients typically have a substantial reduction in potassium stores due to urinary losses, but usually present with normal or even high serum potassium levels due to transcellular potassium shifts. Patients who present with hypokalemia have an even larger potassium deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/46\">",
"     46",
"    </a>",
"    ]. Furthermore, treatment with insulin and intravenous fluids will exacerbate the hypokalemia and minimize the efficacy of potassium repletion. Thus, insulin therapy should be",
"    <strong>",
"     delayed",
"    </strong>",
"    until the serum potassium is above 3.3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    to avoid possible complications of hypokalemia such as cardiac arrhythmias, cardiac arrest, and respiratory muscle weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum potassium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Potassium depletion'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3819731\">",
"     'Manifestations of hypokalemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although isotonic saline is often the initial replacement fluid used in treating diabetic ketoacidosis or nonketotic hyperglycemia, the addition of potassium will make this a hypertonic fluid (since potassium is as osmotically active as sodium), thereby delaying reversal of the hyperosmolality. Thus, 40 to 60 meq of potassium per liter in one-half isotonic saline is preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Potassium depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to patients with marked potassium depletion, patients with hypokalemia due to potassium redistribution (eg, hypokalemic periodic paralysis) have no potassium deficit and even low rates of potassium administration can result in hyperkalemia once the redistributed potassium returns to the extracellular fluid. In a report of patients with hypokalemic thyrotoxic periodic paralysis (baseline serum potassium concentration 2.0",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    administration of potassium at a rate of 10",
"    <span class=\"nowrap\">",
"     meq/hour",
"    </span>",
"    (80",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    resulted in hyperkalemia (&gt;5.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    in 40 percent of patients, one-half of whom had ECG changes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/27\">",
"     27",
"    </a>",
"    ]. Appropriate therapy in these patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=see_link&amp;anchor=H12#H12\">",
"     \"Hypokalemic periodic paralysis\", section on 'Acute treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=see_link&amp;anchor=H7#H7\">",
"     \"Thyrotoxic periodic paralysis\", section on 'Acute treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169061725\">",
"    <span class=\"h4\">",
"     Adverse effects of intravenous potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain and phlebitis can occur during parenteral infusion of potassium into a peripheral vein. This primarily occurs at rates above 10",
"    <span class=\"nowrap\">",
"     meq/hour,",
"    </span>",
"    but can be seen at lower rates. If pain occurs, either the infusion rate or, preferably, the potassium concentration should be reduced.",
"   </p>",
"   <p>",
"    Another potential problem with administering high potassium concentrations in a single infusion container is inadvertent administration of a large amount of potassium in a short period of time, which is more likely to occur when an infusion pump is not used. Since the total extracellular potassium is normally 50 to 70 meq, rapid infusion of 40 to 60 meq of potassium can result in severe hyperkalemia. The following recommended approach should minimize this risk, but careful monitoring is still required. (See",
"    <a class=\"local\" href=\"#H8647610\">",
"     'Careful monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169061747\">",
"    <span class=\"h4\">",
"     Recommended approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with severe hypokalemia due to gastrointestinal or renal losses, the recommended maximum rate of potassium administration is 10 to 20",
"    <span class=\"nowrap\">",
"     meq/hour",
"    </span>",
"    in most patients. However, initial rates as high as 40",
"    <span class=\"nowrap\">",
"     meq/hour",
"    </span>",
"    have been used for life-threatening hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/2,46-48\">",
"     2,46-48",
"    </a>",
"    ]. Rates above 20",
"    <span class=\"nowrap\">",
"     meq/hour",
"    </span>",
"    are highly irritating to peripheral veins. Such high rates should be infused into a large central vein or into multiple peripheral veins.",
"   </p>",
"   <p>",
"    Potassium can be given intravenously via a peripheral or a large central vein. To decrease the risk of inadvertent administration of a large absolute amount of potassium, we suggest the following maximum amounts of potassium that should be added to each particular sized infusion container [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/47,49\">",
"     47,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In any 1000 mL sized container of appropriate non-dextrose fluid, we suggest a maximum of 60 meq of potassium.",
"     </li>",
"     <li>",
"      In a small volume mini-bag of 100 to 200 mL of water that is to be infused into a peripheral vein, we suggest 10 meq of potassium.",
"     </li>",
"     <li>",
"      In a small volume mini-bag of 100 mL of water that is to be infused into a large central vein, we suggest a maximum of 40 meq of potassium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravenous potassium is most often infused in a peripheral vein at concentrations of 20 to 60",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in a non-dextrose-containing saline solution. Use of an infusion pump is preferred to prevent overly rapid potassium administration in any intravenous container with more than 40 meq of potassium or if the desired rate of potassium administration is more than 10",
"    <span class=\"nowrap\">",
"     meq/h.",
"    </span>",
"    For patients with severe hypokalemia, administration in a large central vein is preferred if this access is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8647610\">",
"    <span class=\"h4\">",
"     Careful monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful monitoring of the physiologic effects of severe hypokalemia (ECG abnormalities, muscle weakness, paralysis) is essential. Continuous ECG monitoring or telemetry is warranted in patients with arrhythmias caused by hypokalemia, prolonged QT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other ECG abnormalities attributable to hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], underlying cardiac issues that predispose to arrhythmia in the setting of hypokalemia (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity, myocardial infarction, underlying long QT syndrome), intravenous potassium repletion at a rate greater than 10 meq per hour, and patients at risk for rebound hyperkalemia (most often due to thyrotoxic periodic paralysis). Once the hypokalemia is no longer severe, the rate of intravenous potassium repletion should be reduced or changed to oral therapy. (See",
"    <a class=\"local\" href=\"#H3820392\">",
"     'Mild to moderate hypokalemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Careful monitoring of the serum potassium is also essential. We suggest that the serum potassium should initially be measured every two to four hours to ascertain the response to therapy. If tolerated, this regimen should be continued until the serum potassium concentration is persistently above 3.0 to 3.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and symptoms or signs attributable to hypokalemia have resolved. Thereafter, the dose and frequency of administration can be reduced to that used in mild to moderate hypokalemia since aggressive repletion is no longer required and gastric irritation can be avoided. (See",
"    <a class=\"local\" href=\"#H3820392\">",
"     'Mild to moderate hypokalemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/54/14177?source=see_link\">",
"       \"Patient information: Hypokalemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H419957\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common causes of hypokalemia are gastrointestinal or urinary losses due to vomiting, diarrhea, or diuretic therapy. Hypokalemia may also result from the transient entry of potassium into cells, which is called redistributive hypokalemia. (See",
"      <a class=\"local\" href=\"#H3819676\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Manifestations of hypokalemia include severe muscle weakness, cardiac arrhythmias, renal abnormalities, and glucose intolerance. These signs and symptoms are generally proportionate to the degree and rapidity of the reduction in serum potassium and resolve with correction of the hypokalemia. The risk of arrhythmias from hypokalemia is highest in older patients, patients with organic heart disease, and patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      or antiarrhythmic drugs. (See",
"      <a class=\"local\" href=\"#H3819731\">",
"       'Manifestations of hypokalemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H45915444\">",
"       'General issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The underlying cause of the hypokalemia should be identified, particularly the presence of hypomagnesemia or redistributive hypokalemia. Patients with hypomagnesemia can be refractory to potassium replacement alone, and potassium replacement can result in rebound hyperkalemia in patients with redistributive hypokalemia. Among patients with redistributive hypokalemia due to increased sympathetic tone (as in hypokalemic thyrotoxic periodic paralysis), the administration of a nonselective beta blocker, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      , can rapidly reverse the hypokalemia and associated symptoms. (See",
"      <a class=\"local\" href=\"#H8647773\">",
"       'Hypomagnesemia and redistributive hypokalemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=see_link&amp;anchor=H7#H7\">",
"       \"Thyrotoxic periodic paralysis\", section on 'Acute treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oral potassium preparations include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"       potassium bicarbonate",
"      </a>",
"      or its precursors (potassium citrate,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36036?source=see_link\">",
"       potassium acetate",
"      </a>",
"      ), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=see_link\">",
"       potassium phosphate",
"      </a>",
"      . Potassium chloride can be give in crystalline form (salt substitutes), as a liquid, or in a slow-release tablet or capsule. Potassium bicarbonate or its precursors is preferred in patients with hypokalemia and metabolic acidosis. Potassium phosphate should be considered only in patients with hypokalemia and hypophosphatemia, as might occur with proximal (type 2) renal tubular acidosis associated with Fanconi syndrome and phosphate wasting. (See",
"      <a class=\"local\" href=\"#H3820784\">",
"       'Potassium preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild to moderate hypokalemia (serum potassium 3.0 to 3.4",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      who do not have ongoing urinary potassium losses, we suggest initial oral administration of 10 to 20 meq of potassium given two to four times per day (20 to 80",
"      <span class=\"nowrap\">",
"       meq/day)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H3820392\">",
"       'Mild to moderate hypokalemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potassium therapy is less effective in patients who have chronic stable renal potassium wasting and are in a steady state, such as those on chronic diuretic therapy (at a fixed dose), or Gitelman or Bartter syndrome. In such patients, usual rates of potassium repletion produce only modest elevations in serum potassium. A potassium-sparing diuretic, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      is usually preferred in such patients. (See",
"      <a class=\"local\" href=\"#H23441650\">",
"       'Ongoing losses and the steady state'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features of primary aldosteronism\", section on 'The steady state'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H838162389#H838162389\">",
"       \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'The steady state'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with primary aldosteronism also present with hypokalemia due to renal potassium wasting:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      is preferred for such patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical features of primary aldosteronism\", section on 'Cardiovascular risk'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of primary aldosteronism\", section on 'Aldosterone antagonists'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If a potassium-sparing diuretic is used in combination with potassium supplements, we recommend close monitoring of potassium levels, along with dietary assessment and limitation of dietary potassium intake. This combination must be used with extreme caution in patients with decreased kidney function and in patients on an ACE inhibitor, renin inhibitor,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angiotensin receptor blocker. We suggest monitoring the serum potassium concentration approximately every three to four months in all patients receiving chronic potassium supplementation, or more often if clinically indicated",
"      <strong>",
"       .",
"      </strong>",
"     </li>",
"     <li>",
"      Potassium must be given more rapidly to patients with hypokalemia that is severe (serum potassium less than 2.5 to 3.0",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      or symptomatic (arrhythmias, marked muscle weakness, or rhabdomyolysis). In such patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      can be given orally in doses of 40 meq, three to four times per day or, particularly in patients also treated with intravenous potassium, 20 meq every two to three hours. (See",
"      <a class=\"local\" href=\"#H3820210\">",
"       'Severe or symptomatic hypokalemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe manifestations of hypokalemia or those who are unable to take oral medications, we recommend intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3819731\">",
"       'Manifestations of hypokalemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3820183\">",
"       'Intravenous therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Depending upon the severity of symptoms, intravenous potassium may be given at doses ranging from 20 meq every two to three hours to a recommended maximum rate of potassium administration of 10 to 20",
"      <span class=\"nowrap\">",
"       meq/hour",
"      </span>",
"      for most patients; rates as high as 40",
"      <span class=\"nowrap\">",
"       meq/hour",
"      </span>",
"      have been used for life-threatening hypokalemia. Rates above 20",
"      <span class=\"nowrap\">",
"       meq/hour",
"      </span>",
"      are highly irritating to peripheral veins. When such high rates are given, they should be infused into a large central vein or into multiple peripheral veins.",
"      <br/>",
"      <br/>",
"      In addition, the maximum amount of potassium that is added to each particular sized infusion container should be limited in order to decrease the risk of inadvertent administration of a large absolute amount of potassium. We suggest the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In any 1000 mL sized container of appropriate non-dextrose fluid, we suggest a maximum of 60 meq of potassium.",
"     </li>",
"     <li>",
"      In a small volume mini-bag of 100 to 200 mL of water that is to be infused into a peripheral vein, we suggest 10 meq of potassium.",
"     </li>",
"     <li>",
"      In a small volume mini-bag of 100 mL of water that is to be infused into a large central vein, we suggest a maximum of 40 meq of potassium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous potassium is most often infused in a peripheral vein at concentrations of 20 to 60",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in a non-dextrose-containing saline solution. Use of an infusion pump is preferred to prevent overly rapid potassium administration in any intravenous container with more than 40 meq of potassium or if the desired rate of potassium administration is more than 10",
"      <span class=\"nowrap\">",
"       meq/h.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H169061747\">",
"       'Recommended approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain and phlebitis can occur during parenteral infusion of potassium into a peripheral vein. This primarily occurs at rates above 10",
"      <span class=\"nowrap\">",
"       meq/hour,",
"      </span>",
"      but can be seen at lower rates. If pain occurs, either the infusion rate or, preferably, the potassium concentration should be reduced. (See",
"      <a class=\"local\" href=\"#H169061725\">",
"       'Adverse effects of intravenous potassium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful monitoring of the physiologic effects of severe hypokalemia (ECG abnormalities, muscle weakness, paralysis) is essential. Continuous ECG monitoring or telemetry is warranted in patients with arrhythmias caused by hypokalemia, prolonged QT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other ECG abnormalities attributable to hypokalemia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/2/9258/abstract/18,19\">",
"       18,19",
"      </a>",
"      ], underlying cardiac issues that predispose to arrhythmia in the setting of hypokalemia (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity, myocardial infarction, underlying long QT syndrome), intravenous potassium repletion at a rate greater than 10 meq per hour, and patients at risk for rebound hyperkalemia (most often due to thyrotoxic periodic paralysis).",
"     </li>",
"     <li>",
"      Once the hypokalemia is no longer severe, the rate of intravenous potassium repletion should be reduced or changed to oral therapy. Patients should be treated until the serum potassium concentration is persistently above 3.0 to 3.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and symptoms or signs attributable to hypokalemia have resolved. (See",
"      <a class=\"local\" href=\"#H8647610\">",
"       'Careful monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mount, DB, Zandi-Nejad, K.. Disorders of Potassium Balance. In: Brenner and Rector's The Kidney, Brenner BM (Ed), W.B Saunders Co., Philadelphia 2008. p.547.",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW. Hypokalemia. In: Clinical physiology of acid-base and electrolyte disorders, 5th ed, Rose, BD, Post, TW (Eds), McGraw-Hill, 2001. p.836.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/3\">",
"      Gennari FJ. Hypokalemia. N Engl J Med 1998; 339:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/4\">",
"      Comi G, Testa D, Cornelio F, et al. Potassium depletion myopathy: a clinical and morphological study of six cases. Muscle Nerve 1985; 8:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/5\">",
"      Shintani S, Shiigai T, Tsukagoshi H. Marked hypokalemic rhabdomyolysis with myoglobinuria due to diuretic treatment. Eur Neurol 1991; 31:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/6\">",
"      Dominic JA, Koch M, Guthrie GP Jr, Galla JH. Primary aldosteronism presenting as myoglobinuric acute renal failure. Arch Intern Med 1978; 138:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/7\">",
"      Knochel JP. Neuromuscular manifestations of electrolyte disorders. Am J Med 1982; 72:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/8\">",
"      Knochel JP, Schlein EM. On the mechanism of rhabdomyolysis in potassium depletion. J Clin Invest 1972; 51:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/9\">",
"      van Dinter TG Jr, Fuerst FC, Richardson CT, et al. Stimulated active potassium secretion in a patient with colonic pseudo-obstruction: a new mechanism of secretory diarrhea. Gastroenterology 2005; 129:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/10\">",
"      Blondon H, B&eacute;chade D, Desram&eacute; J, Algayres JP. Secretory diarrhoea with high faecal potassium concentrations: a new mechanism of diarrhoea associated with colonic pseudo-obstruction? Report of five patients. Gastroenterol Clin Biol 2008; 32:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/11\">",
"      Yelamanchi VP, Molnar J, Ranade V, Somberg JC. Influence of electrolyte abnormalities on interlead variability of ventricular repolarization times in 12-lead electrocardiography. Am J Ther 2001; 8:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/12\">",
"      Guo J, Massaeli H, Xu J, et al. Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines. J Clin Invest 2009; 119:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/13\">",
"      Nia AM, Gassanov N, Ortega M, Er F. Drunk potassium channels. Europace 2011; 13:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/14\">",
"      Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA 1992; 267:1083.",
"     </a>",
"    </li>",
"    <li>",
"     Mujais, SK, Katz, AL. Potassium deficiency. In: The Kidney: Physiology and Pathophysiology, Seldin DW, Giebisch G (Eds), Lippincott Williams &amp; Wilkins, 2000. p.1615.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/16\">",
"      Goldstein SA. K2P potassium channels, mysterious and paradoxically exciting. Sci Signal 2011; 4:pe35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/17\">",
"      Ma L, Zhang X, Chen H. TWIK-1 two-pore domain potassium channels change ion selectivity and conduct inward leak sodium currents in hypokalemia. Sci Signal 2011; 4:ra37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/18\">",
"      Chen EH, Hollander JE. When do patients need admission to a telemetry bed? J Emerg Med 2007; 33:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/19\">",
"      Drew BJ, Califf RM, Funk M, et al. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. Circulation 2004; 110:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/20\">",
"      Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med 2000; 160:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/21\">",
"      Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol 2007; 18:2649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/22\">",
"      Yang L, Frindt G, Palmer LG. Magnesium modulates ROMK channel-mediated potassium secretion. J Am Soc Nephrol 2010; 21:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/23\">",
"      Whang R, Flink EB, Dyckner T, et al. Magnesium depletion as a cause of refractory potassium repletion. Arch Intern Med 1985; 145:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/24\">",
"      Zydlewski AW, Hasbargen JA. Hypothermia-induced hypokalemia. Mil Med 1998; 163:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/25\">",
"      Schaefer M, Link J, Hannemann L, Rudolph KH. Excessive hypokalemia and hyperkalemia following head injury. Intensive Care Med 1995; 21:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/26\">",
"      Ahmed I, Chilimuri SS. Fatal dysrhythmia following potassium replacement for hypokalemic periodic paralysis. West J Emerg Med 2010; 11:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/27\">",
"      Lu KC, Hsu YJ, Chiu JS, et al. Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis. Am J Emerg Med 2004; 22:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/28\">",
"      Kim GH, Han JS. Therapeutic approach to hypokalemia. Nephron 2002; 92 Suppl 1:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/29\">",
"      Crop MJ, Hoorn EJ, Lindemans J, Zietse R. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant 2007; 22:3471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/30\">",
"      Sterns RH, Cox M, Feig PU, Singer I. Internal potassium balance and the control of the plasma potassium concentration. Medicine (Baltimore) 1981; 60:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/31\">",
"      Adrogu&eacute; HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore) 1986; 65:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/32\">",
"      Wang CC, Shiang JC, Huang WT, Lin SH. Hypokalemic paralysis as primary presentation of Fanconi syndrome associated with Sj&ouml;gren syndrome. J Clin Rheumatol 2010; 16:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/33\">",
"      Hoorn EJ, Zietse R. Combined renal tubular acidosis and diabetes insipidus in hematological disease. Nat Clin Pract Nephrol 2007; 3:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/34\">",
"      Kassirer JP, Schwartz WB. The response of normal man to selective depletion of hydrochloric acid. Factors in the genesis of persistent gastric alkalosis. Am J Med 1966; 40:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/35\">",
"      KASSIRER JP, BERKMAN PM, LAWRENZ DR, SCHWARTZ WB. THE CRITICAL ROLE OF CHLORIDE IN THE CORRECTION OF HYPOKALEMIC ALKALOSIS IN MAN. Am J Med 1965; 38:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/36\">",
"      Villamil MF, Deland EC, Henney RP, Maloney JV Jr. Anion effects on cation movements during correction of potassium depletion. Am J Physiol 1975; 229:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/37\">",
"      Sopko JA, Freeman RM. Salt substitutes as a source of potassium. JAMA 1977; 238:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/38\">",
"      Aselton PJ, Jick H. Short-term follow-up study of wax matrix potassium chloride in relation to gastrointestinal bleeding. Lancet 1983; 1:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/39\">",
"      Kopyt N, Dalal F, Narins RG. Renal retention of potassium in fruit. N Engl J Med 1985; 313:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/40\">",
"      Wahr JA, Parks R, Boisvert D, et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group. JAMA 1999; 281:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/41\">",
"      Shapiro W, Taubert K. Letter: Hypokalaemia and digoxin-induced arrhythmias. Lancet 1975; 2:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/42\">",
"      Keith, NM, Osterberg, AE, Burchell, HB. Some effects of potassium salts in man. Ann Intern Med 1942; 16:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/43\">",
"      Nicolis GL, Kahn T, Sanchez A, Gabrilove JL. Glucose-induced hyperkalemia in diabetic subjects. Arch Intern Med 1981; 141:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/44\">",
"      Sterns RH, Feig PU, Pring M, et al. Disposition of intravenous potassium in anuric man: a kinetic analysis. Kidney Int 1979; 15:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/45\">",
"      KUNIN AS, SURAWICZ B, SIMS EA. Decrease in serum potassium concentrations and appearance of cardiac arrhythmias during infusion of potassium with glucose in potassium-depleted patients. N Engl J Med 1962; 266:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/46\">",
"      Abramson E, Arky R. Diabetic acidosis with initial hypokalemia. Therapeutic implications. JAMA 1966; 196:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/47\">",
"      Hamill RJ, Robinson LM, Wexler HR, Moote C. Efficacy and safety of potassium infusion therapy in hypokalemic critically ill patients. Crit Care Med 1991; 19:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/48\">",
"      Pullen H, Doig A, Lambie AT. Intensive intravenous potassium replacement therapy. Lancet 1967; 2:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/2/9258/abstract/49\">",
"      Kruse JA, Carlson RW. Rapid correction of hypokalemia using concentrated intravenous potassium chloride infusions. Arch Intern Med 1990; 150:613.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2297 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-042A3B073A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9258=[""].join("\n");
var outline_f9_2_9258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H419957\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3819676\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3819731\">",
"      MANIFESTATIONS OF HYPOKALEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3819896\">",
"      Severe muscle weakness or rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3819903\">",
"      Cardiac arrhythmias and ECG abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3819925\">",
"      Renal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45000008\">",
"      Glucose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3819951\">",
"      PATHOGENESIS OF SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60964434\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3820122\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45915444\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8647773\">",
"      - Hypomagnesemia and redistributive hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2860406\">",
"      Estimation of the potassium deficit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12019917\">",
"      - Uncontrolled diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3820784\">",
"      Potassium preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3820183\">",
"      - Intravenous therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23441650\">",
"      Ongoing losses and the steady state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H465021\">",
"      Potassium-sparing diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3820392\">",
"      Mild to moderate hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3820210\">",
"      Severe or symptomatic hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18820461\">",
"      - Intravenous potassium repletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H169061725\">",
"      Adverse effects of intravenous potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H169061747\">",
"      Recommended approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8647610\">",
"      Careful monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H419957\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2297\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2297|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/49/38685\" title=\"figure 1\">",
"      Thiazide side effects and dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2297|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/21/40284\" title=\"table 1\">",
"      High potassium foods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2297|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?18/38/19043\" title=\"waveform 1\">",
"      Hypokalemia tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=related_link\">",
"      Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=related_link\">",
"      Causes of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9366?source=related_link\">",
"      Evaluation of the patient with hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=related_link\">",
"      Hypokalemia-induced renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=related_link\">",
"      Hypokalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14137?source=related_link\">",
"      Myopathies of systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/54/14177?source=related_link\">",
"      Patient information: Hypokalemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13060?source=related_link\">",
"      Potassium and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=related_link\">",
"      Thyrotoxic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=related_link\">",
"      Treatment of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_2_9259="Dyspepsia alarm features AGA";
var content_f9_2_9259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Alarm features in dyspepsia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Age older than 55 years with new-onset dyspepsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of upper gastrointestinal cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unintended weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive dysphagia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Odynophagia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained iron deficiency anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palpable mass or lymphadenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaundice",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129:1756.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9259=[""].join("\n");
var outline_f9_2_9259=null;
var title_f9_2_9260="Disorders associated with bacterial overgrowth";
var content_f9_2_9260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders associated with bacterial overgrowth",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Small intestinal stasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Anatomic abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Small intestinal diverticulosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Surgically created blind loops (end-to-side anastomosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Strictures (Crohn's disease, radiation, surgery)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Abnormal small intestinal motility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scleroderma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Idiopathic intestinal pseudoobstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Radiation enteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abnormal communication between the proximal and distal gastrointestinal tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrocolic or jejunocolic fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resection of the ileocecal valve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Associations usually with multifactorial causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypochlorhydria due to atrophic gastritis or medications. These are usually not clinically significant unless there coexist concomitant motility disturbances of the small bowel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunodeficiency states (common variable immunodeficiency, AIDS, severe malnutrition)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcoholism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        End stage renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Advanced age",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9260=[""].join("\n");
var outline_f9_2_9260=null;
var title_f9_2_9261="Flow volume loop in RPC";
var content_f9_2_9261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flow-volume loop in relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 279px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow-volume loop in relapsing polychondritis showing a very low flow rate during expiration due to severe expiratory flow obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9261=[""].join("\n");
var outline_f9_2_9261=null;
var title_f9_2_9262="Time course of insulin action";
var content_f9_2_9262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Effect of twice-daily insulin regimen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Twice-daily administration of regular (solid lines) and intermediate-acting lente or NPH (dashed lines) insulins before breakfast and the evening meal provides peaks of insulin after the injections as well as a relatively constant baseline level of insulin throughout the day after injections of the intermediate-acting insulins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9262=[""].join("\n");
var outline_f9_2_9262=null;
var title_f9_2_9263="Cut off value";
var content_f9_2_9263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Importance of cut-off value on test performance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    As the cut-off value is moved to the left, sensitivity (the true positive rate) increases, but specificity decreases.",
"    <div class=\"footnotes\">",
"     TN: true negatives; TP: true positives; FN: false negatives; FP: false positives.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_2_9263=[""].join("\n");
var outline_f9_2_9263=null;
